TOLL FREE: 888.88.INFECT
PHONE: 517.536.8210
FAX: 517.536.8205

THE WELLHOFF CENTER
7190 S. BROOKLYN RD.
JACKSON, MI 49201

TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Newsletters

December 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A note from your President & CEO,

Another year has gone by quickly and 2015 is right around the corner. This January marks our seven year anniversary. It is hard to believe that eight years has passed since Pfizer R & D closed its doors in Ann Arbor, Michigan. January 22nd, 2007 marks the announcement day that made all of us wonder what would happen after Pfizer. I was one of the lucky ones that had a plan shortly after the announcement and that plan was founding TransPharm Preclinical Solutions. We incorporated on April 13th 2007, started renovation to the lab in September of that year and opened our doors on January 2nd, 2008.

Today we are considered a global leader for Infectious Disease research and have generated more than 6 million in revenue with over 60 clients around the world. TransPharm has never been stronger and we are eager to see what the future holds for us. During the Holidays, we are very thankful to do what we love and even more thankful to you for allowing us to do this important work.

Dan

Slight Increase in Pricing

Starting in January, TransPharm will be increasing the cost of our studies due to increases in costs from some of our suppliers. We expect the increase to be 5% across the board for all studies, but this could vary depending on study design. Studies booked for January that are scheduled in December will remain at the current price structure.

Holiday Schedule

TransPharm will be closed this month starting around noon on December 24th and reopen on January 5th. All studies must end no later than the 24th with preliminary data following mid day. All mouse orders scheduled for January 5th must be placed before December 24th. No animals will be on site during this closure. Now is the time to get your studies scheduled for January.

June 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A note from your President & CEO,

I would like to wish a happy summer to all of you. As we move into warmer weather, vacations and outdoor activities seem to fill our days and time to get things done seems to shorten. Towards that end, I will be brief with this newsletter and want to say that TransPharm has finally been awarded PHS registry with the Office of Laboratory Animal Welfare.

Briefly, this means that companies receiving grant funds from NIH are now allowed to spend those funds directly with TransPharm Preclinical Solutions. This is a huge milestone for us and I know it will open the doors to many of the smaller companies receiving grant funds. Please see the notice below and use our Assurance # A4707-01 for all future grant applications to the National Institute of Health.

Dan

21

As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC

March 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A note from your President & CEO,

At last, I’ve found a few moments to reconnect with our distribution list which is growing every month. TransPharm finished very strong in 2013, recording our second best year. We’ve also picked up some new clients in the last few months and would like to welcome them to the TransPharm family. I’m very proud to say that we have continued to work with a few clients that have been here since we’ve opened.

As the saying goes, “Working with us is Contagious”…….

Quickly, I would like to address a single question a few of you have about another large project in the works and how it relates to TransPharm and my goals going forward.

I was lucky enough to have an opportunity to purchase a piece of history here in the Irish Hills area where I live. The facility is an original Henry Ford Village Industries site built in the late 1930’s. The plot of land it sits on was the first parcel of land deeded in Brooklyn back in 1832.

The plan for this facility is to turn it into an Irish themed destination called the Old Irish Mill. It will include a restaurant, pub, café, a park and Michigan’s largest indoor farmer market. We are very excited about this venture and know it will become one of the favorite tourist stops in the area.

So what will happen to TransPharm??? Am I leaving??? Who is going to run the show???

Rest assured, nothing will be changing around here any time soon. My role in this new venture is simply the idea and finance guy. I’m currently involved with a lot of the interior demolition and spearheading the general contracting, but that is to get things going in the right direction. I don’t plan to have an active role in the new organizational chart once the facility is up and running. I will likely pass along the progress on this project as it moves forward.

Dan

TransPharm named Business of the Year

Annette Dupuie, left, presented Dan and Samantha Ross with a plaque naming their company, TransPharm Preclinical Solutions, as the Brooklyn-Irish Hills Chamber of Commerce Business of the Year for 2014.

Annette Dupuie, left, presented Dan and Samantha Ross with a plaque naming their company, TransPharm Preclinical Solutions, as the Brooklyn-Irish Hills Chamber of Commerce Business of the Year for 2014.

Dan Ross, owner of TransPharm Preclinical Solutions in Napoleon, was surprised when he learned his company was being named Business of the Year by the Brooklyn-Irish Hills Chamber of Commerce.

“It is not often that I am speechless,” said Ross. “I really had no idea.”

This year’s Business of the Year opened its doors in January of 2008; they joined the chamber right away. Recently stating that being part of our chamber is like one big family. These owners are adamant about supporting chamber members businesses’ and organizations. They have received many awards and certificates nationally, ranking in the top 2% of all globally accredited facilities. They have even made it on National news, ABC World News with Diane Sawyer. In 2011, this business was named one of the “Michigan 50 Companies to Watch” I have even heard them say they have an open door policy, meaning that ANYONE can schedule a tour to walk through their facility.

Their level of commitment to this community and our Chamber is valued, seeing as most of their business attracts customers from across the United States and even internationally. They have been major sponsors of many of the Chamber fundraisers including the Legacy Sponsor for the last 3 years at the All Sports Spectacular. Other community events they are involved in are the Oh These Irish Hills ‘Row, Row, Row your cardboard boat,’ driving a car for the ‘Distinguished Young Women’ in the Christmas Parade, The Great American Crab Races at The Beach Bar, they even sponsored a little league softball team called the ‘Cootie Killers.’

Their vision of the Old Irish Mill, the former Ford Motor Co. plant in Brooklyn, is inspiring to see what this team has to bring to our community.

Because working with them IS contagious… please join me in congratulating TransPharm Preclinical Solutions, This year’s Business of the Year.

New C. difficile Offerings

Over the past several quarters, the TransPharm team has been busy performing numerous C. difficile studies and looking for ways to best serve our client’s needs. As a result, we’ve added two new offerings to complement our robust model of C. difficile infection. These new features are Toxin A/B detection and recurrence studies.

The commercially available R-Biopharm RIDASCREEN® kit can be used to detect the presence of C. difficile Toxin A/B in stool samples. This is a great data set for our clients to complement the clinical scoring and weight loss observations.

We have also validated a longer version of our current C. difficile infection model to capture the recurrence event seen in the clinical setting. With mice receiving a C. difficile challenge on Day 0, and vancomycin QD from Days 0-4, we see recurrence on Day 8 as indicated by mortality and significant weight loss.

We feel these two new, clinically-relevant features will be advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information.

Dr. Santiago R. Lopez
Director of Research

 

As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC

November 2012

Posted by on 12:41 pm in Newsletters | 0 comments

President’s Letter:

It is hard to believe another year has come and gone, but here we are again. Getting bundled up and trying to stay warm is never easy, but it is hard to beat the beauty of Michigan in the fall season. The picture below was taken in early October just outside the TransPharm facility. We are extremely lucky to be surrounded by 15 acres of trees, a pond and having the Northern property line border on Stoney Lake Creek. Visiting clients are always pleasantly surprised by our location and the country feel of our facility. One client in particular was taken back by the flock of wild turkeys outside our lab window. I was told that he doesn’t get to see that in France. It’s not uncommon to see deer strutting through the grounds or the occasional fox.

We truly do have a unique setting and would like to use this opportunity to invite you to come out and visit. I cant guarantee that the wildlife will cooperate and offer you a glimpse, but I can guarantee that you will be impressed with our AAALAC accredited facility, inside and out.

Dan

17

 

The Next Level

During this holiday season, the TransPharm team has been busy brainstorming and researching the possibilities of taking our services to the next level…the next Biosafety Level that is. We’ve met with consultants and engineers concerning the best approach to upgrade our current, state-of-the art facilities to a BSL 3 laboratory. This will provide our clients with even more infection models with which to screen their antimicrobials. Client inquiries into level 3 models have allowed us to formulate a list of top-priority model validations which include: tuberculosis, anthrax, brucellosis and rickettsial diseases. Of course, this would only be the beginning of potential models we could offer to our clients. If you have a request for early validation of a specific model, please don’t hesitate to contact us! Have a wonderful holiday season and we look forward to working with you in 2013.

Dr. Santiago R. Lopez
Director of Research

 

 

Holiday Office Hours:

This is a reminder that the TransPharm offices and vivarium will be closed this year starting on December 21st and will reopen on January 2nd. The last day for mouse deliveries is December 17th with studies ending on the 20th. Studies for early January should be booked before December 21st.

We will be checking email periodically. This is the best way to reach us during our Holiday break. Have a great Holiday season and a wonderful New Year.

The TransPharm Team

As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC

July 2012

Posted by on 12:46 pm in Newsletters | 0 comments

President’s Letter:

I’m proud to start out this newsletter by letting you know that TransPharm Preclinical Solutions has once again received recommendation for accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International.

AAALAC accreditation is evaluated every three years, with our recent site visit on July 20th. Programs constantly change, along with the regulations in the use of animals in research. AAALAC’s mission is to ensure that all of these changes are in force and the Program Description for our facility is accurate, complete and adhered to. The continued success of our program is directly related to those individuals on our Institutional Animal Care and Use Committee, or IACUC. I would like to personally thank all those individuals.

  • Libby Ziemke, IACUC administrator
  • Marci Peek, Chair
  • Dr. Megan Nowland, attending Veterinarian and Alternate Chair
  • Joanne Zammit, Scientist
  • Dr. Santiago Lopez, Scientist
  • Dan Wymer, Non-Scientist
  • Dr. Jim Mobley, Alternate scientist

Adhering to these global standards is what lead to our success three years ago. This continued recommendation for accreditation bodes well for our continued success.
To learn more about AAALAC International please visit: www.aaalac.org

Towards our commitment for high quality research, four individuals here at TransPharm have recently taken their respective level of certification through the American Association of Laboratory Animal Science. AALAS offers these nationwide board exams after certain criteria is met by the individual taking the exam. I would like to congratulate:

  • Heidi Richardson, ALAT level
  • Marci Peek, LAT level
  • Libby Ziemke, LATG level
  • Lisa Lazaroff, LATG level

To learn more about AALAS please visit www.aalas.org

Dan

Clostridium difficile murine model

In an effort to provide our clients with the most robust and effective murine models of infection, TransPharm has adopted a new bacterial spore preparation for our C. difficile-associated disease model. This improved protocol has been thoroughly validated and rigorously compared to our previous procedure. It has surpassed TransPharm’s high standard of scientific excellence (Figures 1-3), much to the satisfaction of our valued clients with whom we’ve had the pleasure of collaborating.

CDAD-MortalityCDAD-Body WeightsCDAD-Fecal

So, if your group is in the market for a murine model of C. difficile-associated disease (or any other infectious disease model), there’s no better time to talk with us! Don’t forget – PK studies are also available here at TransPharm.

Dr. Santiago R. Lopez
Director of Research

ICAAC 2012

TransPharm will be in attendance at the 2012 ICAAC conference in San Francisco this year taking place September 9th – 12th. There have been many positive changes within TransPharm since the 2011 ICAAC in Chicago, including new animal models, management and additions to our scientific team. Our new Director of Research, Dr. Santiago Lopez will be joining us in San Francisco. Please stop by booth #1014 and welcome him to his first ICAAC.

As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on FaceBook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC

April 2012

Posted by on 12:07 pm in Newsletters | 0 comments

President’s Letter:

TransPharm has given me some wonderful opportunities over the last 4 years. Locally, we volunteer for Junior Achievement, Big Brothers/Big Sisters, and donate to numerous charities that I wouldn’t have been able to do in the past.

At the state level, we were awarded as one of the Top 50 Companies to Watch in Michigan in 2011. I was invited to a business round table discussion and met with Jennifer Granholm, Michigan’s outgoing Governor. In the last two months, I was invited to Governor Rick Snyder’s residence in Lansing for the Moores River Drive Breakfast. Both events brought together many of the States business leaders and gave us a chance to meet with many of our States representatives and hear some of the new initiatives that are in the works for small business owners.

At the national level, TransPharm has traveled to both the East and West Coast and many cities in between to attend the annual ICAAC conference. This year’s event is being held in San Francisco, California. Please stop by booth 1014 and say hi.

Of all the things that have made me feel extremely lucky, was the recent International experience of traveling to London, England to attend the European Congress of Clinical Microbiology and Infectious Diseases. The conference boasts attendance from 106 different countries. It was my first trip to Europe and I can’t overstate how wonderful it was. Ironically, I met a family in our hotel that lives about 25 miles from me in Michigan. It goes to show how small this world is these days. I’m already looking forward to attending the conference next year in Berlin, Germany.

Dan

London Tower Bridge visit during the ECCMID conference

London Tower Bridge visit during the ECCMID conference

TransPharm’s Development Incubator

To update you on our current model development here at TransPharm, I’d like to announce that our first viral sepsis model, Herpes Simplex Virus 1, is just about completed! Once the finishing touches are added within the next few days we’ll be ready to roll this out to all our interested clients (Figure 1). Also while the viral models are emerging from our development incubator, we’ve also established a neonatal rat sepsis model using Staphylococcus epidermidis (Figure 2). This model mimics the clinical manifestation sometimes seen in low birth weight human infections.

Figure 1 - HSV-1Figure 2 - S epidermidis

In recent months, a new, advantageous partnership has emerged between TransPharm and HuMurine Technologies (www.humurine.com). Using their proprietary Hu-M™ CIEA NOG mouse® model as a background, HuMurine has developed a commercialized humanized mouse, named the Hu-M™ ID Model, to study infectious disease. With their novel humanized mouse model and TransPharm’s preclinical testing experience, this joint venture has the potential to greatly benefit institutions that desire to test compound efficacy in a preclinical, human immunological environment. We are looking to develop a hu-mouse model for all current TransPharm pathogens, as well as new ones such as Malaria and Dengue. Stay tuned for updates on this exiting, new partnership!

Dr. Santiago R. Lopez
Director of Research

Dan Ross, President & CEO of TransPharm was recently interviewed by the Michigan Business Network. Click the link below to listen to the Podcast

http://www.michiganbusinessnetwork.com/radio/2012/03/09/Business_Beat_S2_Daniel_Ross

As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on FaceBook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC

January 2012

Posted by on 11:33 am in Newsletters | 0 comments

President’s Letter:

Let me be the last person to wish you a Happy New Year! 2011 proved to be a year full of challenges and rewards for us here at TransPharm. We have had many requests to run in vivo models of pathogens we have not yet validated. While it’s nearly impossible to have data in hand for all the possible requests we could see, we are now fully committed to putting more resources into new project validations. TransPharm has many new models that we plan to roll out in 2012 and Dr. Lopez will touch on a few of those below. Marci Peek, our Contract & Protocol Specialist, will also inform you of some news regarding our product, the Final Report.

We closed the year with a 15% increase in revenue over 2010, making it our best year to date. This is one reason TransPharm will be making new commitments to our clients in 2012. Our pricing structure will remain untouched, new models will be rolled out and our new Final Report Guarantee are just a few ways we are saying thank you for your business.

Dan

TransPharm is going viral!

The year 2012 promises many exciting projects for the Research and Development team here at TransPharm! One of these projects involves the expansion of our current models of infection to now include viral models, namely Herpes Simplex Virus (HSV) types 1 and 2. With the various clinical manifestations of this pathogen and its worldwide spread, we believe HSV is a logical entry point into the viral infection modeling realm. TransPharm is currently in the process of developing and validating both an in vitro model to detect early viral mRNA transcripts as well as an in vivo sepsis model of HSV infection. We have also laid the groundwork to explore the murine model of latency and reactivation of all herpes viruses.

Another area of research we are excited about is the development of a mouse model for malaria infections (Plasmodium falciparum). Being the world’s second biggest killer (just behind tuberculosis) and with relatively little research going into anti-malaria medications, TransPharm believes this model will aid in the search for cost-effective treatments for this deadly disease. So stay tuned for updates regarding TransPharm’s upcoming infection models!

Please contact me directly if you have any questions or if you have any specific needs related to these models.

Dr. Santiago R. Lopez
1-888-88-INFECT

“Final Report Guarantee”

Historically, TransPharm has aimed for a turn-around time of approximately 2 months from study end to delivery of the final report to the client. Unfortunately, this time line was not always able to be met. In 2012, however, we are confident that we will be able to consistently meet an even tighter time line of 1 month or less between study end and final report delivery. We have made some changes internally and fully expect to fulfill this goal. If for any reason we fail to meet this timeline, we will deduct $200 off the client’s final payment request.

And as always, clients will receive their raw data package within 1 week of study completion, in the form of an Excel spreadsheet with data analyses included.

Marci Peek
Contracts and Protocol Specialist
1-517-536-8229

 

As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on FaceBook

Sincerely,
Daniel Ross
President & CEO
TransPharm Preclinical Solutions, LLC